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Abstract: Tedizolid phosphate (TR-701), a prodrug of tedizolid (TR-700), is a next-generation 
oxazolidinone that has shown favorable results in the treatment of acute bacterial skin and 
skin-structure infections in its first Phase III clinical trial. Tedizolid has high bioavailability, 
penetration, and tissue distribution when administered orally or intravenously. The activity 
of tedizolid was greater than linezolid against strains of Staphylococcus spp., Streptococcus 
spp., and Enterococcus spp. in vitro studies, including strains resistant to linezolid and those 
not susceptible to vancomycin or daptomycin. Its pharmacokinetic characteristics allow for a 
once-daily administration that leads to a more predictable efficacy and safety profile than those 
of linezolid. No hematological adverse effects have been reported associated with tedizolid 
when used at the therapeutic dose of 200 mg in Phase I, II, or III clinical trials of up to 3 weeks 
of tedizolid administration. Given that the clinical and microbiological efficacy are similar for 
the 200, 300, and 400 mg doses, the lowest effective dose of 200 mg once daily for 6 days was 
selected for Phase III studies in acute bacterial skin and skin-structure infections, providing a 
safe dosing regimen with low potential for development of myelosuppression. Unlike linezolid, 
tedizolid does not inhibit monoamine oxidase in vivo, therefore interactions with adrenergic, 
dopaminergic, and serotonergic drugs are not to be expected. In conclusion, tedizolid is a novel 
antibiotic with potent activity against Gram-positive microorganisms responsible for skin and 
soft tissue infections, including strains resistant to vancomycin, linezolid, and daptomycin, thus 
answers a growing therapeutic need.
Keywords: oxazolidinone, TR-700, TR-701 FA, tedizolid, skin and soft tissue infections, 
linezolid resistance
Introduction
Skin and soft tissue infections are one of the main reasons people seek health care 
and account for approximately 7%–10% of US hospital admissions.1,2 During the 
2000–2004 period there was a 28.9% increase in the number of hospitalizations due 
to skin and soft tissue infections.3 A study conducted in Taiwan reported that approxi-
mately 7.7% of hospitalized patients presented with at least one skin and soft tissue 
infection during the 2005–2007 period.4
Despite the fact that the etiology can be variable, Staphylococcus aureus is the 
microorganism most often involved.5 In recent years, an increase has been observed 
in the number of methicillin-resistant S. aureus (MRSA) strains, which makes the 
management of these infections more difficult. Thus, the rate of methicillin resistance 
in S. aureus strains from skin and soft tissue infections ranges from 22.8% in Europe 
to 35.9% in North America.5
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Previously, infections due to MRSA strains were limited 
to the hospital setting. However, in the last decade, there has 
been an emergence of community-associated MRSA strains. 
For instance, a 59% prevalence of MRSA strains has been 
reported (range: 15%–74%) in patients with skin and soft 
tissue infections who were admitted to emergency wards in 
eleven US cities.6 The USA 300 strain was identified in 97% 
of MRSA strains. Its high capacity for diffusion means that 
the USA 300 strain is now considered to be epidemic in the 
USA and is becoming significant in other parts of the world.7 
Moreover, a decrease in this strain’s sensitivity to several 
antibiotics has been observed, which could make the success 
of antibiotic treatment even more difficult.7 New clones of 
community MRSA have been reported to be on the rise in 
other European countries.8,9
Currently, the emergence of community-associated and 
hospital-origin MRSA strains from patients with skin and 
soft tissue infections seems to be under control.10 According 
to a recent study, the rate of skin and soft tissue infections 
due to community MRSA ranged from 76.8 (75.0–78.6) 
per 100,000 people/year in 2005 to 64.0 (62.4–65.6) per 
100,000 people/year in 2010 (P = 0.62).10 Thus, 60% of 
skin and soft tissue infections were caused by MRSA strains 
in 2005, with an increase of up to 62% in 2006 and a sig-
nificant annual reduction reaching 52% in 2010. In addition, 
the rate of hospital MRSA infections decreased from 0.7 
(0.5–0.8) per 100,000 people/year in 2005 to 0.4 (0.2–0.5) per 
100,000 people/year in 2010 (P = 0.02). No trend was observed 
in the percentage of infections due to MRSA strains when the 
origin of the infections was the hospital (P = 0.96).
Vancomycin is the antibiotic that has been used most 
often to treat infections due to MRSA strains. However, 
its efficacy has been compromised by the emergence of 
S. aureus strains with heteroresistance to glycopeptide 
 (heterogeneous vancomycin-intermediate S. aureus [hVISA] 
strains), intermediate resistance (vancomycin-intermediate 
S. aureus [VISA] strains) and, occasionally, complete resis-
tance (vancomycin-resistant S. aureus strains).11–14
Linezolid was the first representative member of the 
oxazolidinone family introduced into the pharmaceutical 
market. Although it continues to show excellent activity, 
in recent years, MRSA strains have been isolated that are 
resistant to this antibiotic (minimum inhibitory concen-
tration [MIC] .8 mcg/mL) due to the mutations in 23S 
ribosomal (r) RNA (namely G2576T) or ribosomal protein 
L3 or by the presence of the cfr gene.15,16 The presence of 
the cfr gene confers additional resistance to a high number 
of protein synthesis inhibitors (phenicols, lincosamides, 
 streptogramins, pleuromutilins, oxazolidinones, and 
16-membered macrolides)17–19 and it has the capacity for 
horizontal transfer via mobile genetic elements.20,21
Other antibiotics have been incorporated into the available 
therapeutic arsenal to compensate for the emergence of resistant 
strains, although we consider their use is not without limitations.
A close correlation has been described between the reduc-
tion in sensitivity to daptomycin and resistance to vancomycin 
in VISA and hVISA strains.22,23 This finding irequires precau-
tion when considering daptomycin as a therapeutic alternative 
in infection due to VISA or hVISA strains. In terms of its 
safety profile, several severe cases of daptomycin-induced 
eosinophilic pneumonia24 have been described and treatment 
requires monitoring for possible muscular toxicity associated 
with the antibiotic. In particular, patients with impaired renal 
function or on concomitant treatment with statins should be 
monitored more closely.25
As a result of these issues and given the limited number of 
therapeutic options available for these infections, new thera-
peutic alternatives are being and have been developed for the 
treatment of skin and soft tissue infections, especially those 
produced by resistant Gram-positive microorganisms. One 
such new development is tedizolid (TR-700), which belongs 
to the family of oxazolidinones and is the active moiety of 
tedizolid phosphate (TR-701). One of its greatest advantages 
is that its activity is greater than that of vancomycin and 
linezolid against microorganisms involved mainly in skin 
and soft tissue infections, including strains of S. aureus that 
carry the cfr gene, which, as mentioned, confers resistance 
to linezolid.20,26 Another of its advantages, which it shares 
with linezolid, is its availability both for parenteral and oral 
administration, allowing for outpatient treatment.
This review will describe the role of tedizolid phos-
phate (TR-701) in the treatment of skin and soft tissue 
infections.
Pharmacology
Tedizolid (TR-700 or DA-7157; formerly torezolid) is a 
next-generation oxazolidinone whose chemical differences 
compared with first-generation oxazolidinones grant it 
greater potency, a better spectrum of activity, and a lower 
resistance profile.
In addition to other advantages that will be listed further 
on in this paper, the prodrug tedizolid phosphate (TR-701 
or DA-7218 or DA-7158; formerly torezolid phosphate) 
shares with linezolid the ability to be administered orally and 
intravenously; good bioavailability, tissue penetration, and 
distribution; and good activity against MRSA.27
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Tedizolid phosphate is a basic compound with a molecular 
weight of 494.28 and chemical structure (R)-[3-(4-(2-(2-
methyl tetrazole-5-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-
5-oxazolidinyl] methyl disodium phosphate, which is 
hydrolyzed by phosphatases to the active moiety tedizolid 
(R)-3-(4-(2-(2-methyl tetrazole-5 yl)pyridin-5-yl)-3 
fluorophenyl)-5-hydroxy methyl oxazolidine-2-one.28
Mechanism of action
In a similar fashion to linezolid, tedizolid inhibits the synthe-
sis of bacterial proteins by binding to the 50S subunit of the 
ribosome and preventing the formation of the “70S complex” 
formed by the binding of N-formylmethionine-tRNA, the 
50S subunit, and the 70S subunit. In this way, it prevents the 
translation process in the first step of protein synthesis.29,30
Pharmacokinetics
Absorption, distribution, metabolism,  
and excretion
A study evaluated the pharmacokinetics in a murine model 
of tedizolid phosphate administered intravenously at doses 
of 5, 10 and 20 mg/kg and orally at doses of 20, 50, and 
100 mg/kg, and of tedizolid 10 mg/kg administered both 
intravenously and orally.28 Dose-proportional pharmacoki-
netics were observed for all the doses evaluated. The oral 
administration of tedizolid phosphate resulted in rapid gas-
trointestinal absorption, with tedizolid detected in plasma 
within 15 minutes (time to maximum concentration [T
max
]: 
25.5–65.0 minutes). Plasma area-under-the-curve (AUC) 
values for tedizolid were proportional to the doses of tedizolid 
phosphate administered. Similarly, the formation of tedizolid 
from tedizolid phosphate intravenous (IV) was rapid: it was 
detected in plasma at the first blood sampling time (1 minute) 
and rapidly reached T
max
 (7.85–12.1 minutes) for the three 
doses studied. The AUC values for tedizolid detected in blood 
were proportional to the IV doses of tedizolid  phosphate. 
Both tedizolid phosphate (oral and IV) and tedizolid were 
practically undetectable in urine after 24 hours and in 
the gastrointestinal tract of the animals, including feces. 
Another study analyzed the pharmacokinetics of tedizolid 
phosphate after the administration of a dose of 10 mg/kg in 
rats administered by both oral and IV routes.31 Table 1 shows 
the pharmacokinetic parameters of tedizolid phosphate and 
tedizolid after the administration of tedizolid phosphate to 
rats corresponding to these two studies.28,31
The pharmacokinetics of tedizolid phosphate in other 
species, such as rats and dogs has also been investigated.32 
As in the two studies already discussed, tedizolid phosphate 
administered orally and intravenously was rapidly trans-
formed into tedizolid both in vivo and in vitro in all the 
species analyzed.
In healthy humans, a bioavailability of 91.47% has been 
estimated after the oral administration of a dose of 200 mg of 
tedizolid phosphate.33 Although one study found an increase 
in the T
max
 value and reduction in the maximum concentration 
(C
max
) value of tedizolid after 10 hours of fasting, the AUC 
value was similar both with fasting and when administered 
with food. Thus, since AUC is the most important predictor 
Table 1 Pharmacokinetic parameters of tedizolid phosphate and tedizolid after the administration of tedizolid phosphate to rats28,31
Tedizolid phosphate IV Tedizolid phosphate OR
Dose (mg/kg) 5 mg/kg  
(n = 7)28
10 mg/kg  
(n = 7)28
20 mg/kg  
(n = 9)28
10 mg/kg31 20 mg/kg  
(n = 10)28
50 mg/kg  
(n = 8)28





313 ± 75.4 44.7 ± 16.9 86.3 ± 27.9 3.216 44.7 ± 16.9 86.3 ± 27.9 163 ± 40.0 2.988
T½ (min) 13.8 ± 3.64 133 ± 30.8 159 ± 32.1 205.2 133 ± 30.8 159 ± 32.1 162 ± 29.6 229.2
Cmax (mcg/mL) – – – 8.81 0.214 ± 0.0833 0.320 ± 0.102 0.440 ± 0.0995 8.37
Tmax (min) – – – – 45.0 ± 24.5 80.6 ± 26.5 130 ± 73.5 30
Cl (mL/min/kg) 16.0 ± 3.40 45.0 ± 24.5 80.6 ± 26.5 3.11 – – – –
vdss (mL/kg) 84.7 ± 14.2 0.214 ± 0.0833 0.320 ± 0.102 0.918 – – – –
F (%) – – – – 3.44 2.66 2.51 92.8
Tedizolid IV Tedizolid OR
AUC  
(mcg * min/mL)
905 ± 105 1.780 ± 334 4.070 ± 1.140 2.890 ± 857 8.580 ± 3.230 17.500 ± 6.710
T½ (min) 106 ± 12.0 112 + 19.2 115 ± 29.8 158 ± 24.5 276 ± 113 366 ± 85.7
Cmax (mcg/mL) 12.5 ± 1.16 20.8 ± 3.41 45.4 ± 8.95 14.0 ± 4.43 22.9 ± 8.13 34.6 ± 10.1
Tmax (min) 12.1 ± 4.88 7.85 ± 4.88 10.6 ± 12.6 25.5 ± 14.2 43.1 ± 24.6 65.0 ± 72.3
Abbreviations: AUC, area under the curve; Cl, total body clearance; Cmax, maximum concentration; F, absolute oral bioavailability; Iv, intravenous; OR, oral; T½, half-life; 
Tmax, time to maximum concentration; vdss, volume of distribution at steady state.
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of efficacy,34 there are no dietary restrictions for taking the 
drug.35
Similar to the animal models,32 tedizolid phosphate 
administered orally or intravenously is rapidly transformed 
into tedizolid through hydrolysis of the phosphate group by 
phosphatases.27 In addition, tedizolid was the major moiety 
detected (94.54%–98.23% of radioactivity administered) in 
plasma in a study that evaluated the oral administration of a 
single dose of radioactively labeled tedizolid phosphate in 
healthy adults.36
Two studies have evaluated the pharmacokinetics of tedi-
zolid after the administration of multiple doses of tedizolid 
phosphate in healthy adults (Table 2).33,37 In one of them 
linezolid was used as a comparator treatment.37
The pharmacokinetic parameters of tedizolid have been 
determined in other studies in which increasing single 
doses of tedizolid phosphate were administered, both orally 
(200–1200 mg)38 and intravenously (100–400 mg).33 Less 
variability was observed in the systemic exposure of tedizolid 
when it was compared with linezolid.37 Thus, the pharma-
cokinetic parameters of tedizolid corresponding to day 1 
were predictive of those observed at steady state.33,37 As in 
the animal models, the AUC and C
max
 values of tedizolid 
showed linear pharmacokinetics almost proportional to the 
tedizolid phosphate dose, both in the studies with multiple 
doses and with single doses.37,38
Two studies have evaluated a model that reflects the 
superior pharmacokinetics of tedizolid phosphate.39,40 In a 
Phase II dose-ranging study of efficacy and tolerability of 
200, 300, and 400 mg of tedizolid phosphate in the treatment 
of complicated skin and skin-structure infections, clinical 
cure and microbiological eradication rates were above 90% 
with all three doses.40 Population pharmacokinetics favored a 
two-compartment model over one disposition  compartment. 
In the other Phase II study, nonlinear mixed effects model-
ing was performed to analyze pharmacokinetics of tedizolid 
phosphate in patients with acute bacterial skin and skin-
structure infections (ABSSSI).39 Results showed that the 
pharmacokinetics was well described by a two-compartment 
model with zero-order dose delivery to the depot compart-
ment and subsequent first-order absorption.
Plasma protein binding in healthy adults has been estimated 
between 86.1% and 91.9%, with a mean of 89.44% ± 1.58%.41
The volume of distribution of tedizolid has been reported 
to be between two and three times higher than the value 
observed with linezolid.37 Further, in a study with healthy 
adults, it was observed that the levels of free tedizolid in 
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in plasma after the oral administration of a single dose of 
600 mg of tedizolid phosphate.42 Ratio of unbound AUC in 
tissues over unbound (free) AUC in plasma (fAUC tissue/
fAUC plasma) of tedizolid was 1.1 ± 0.2 in adipose tissue 
and 1.2 ± 0.2 in muscle tissue. These values, together with the 
rest of the pharmacokinetic parameters, support the admin-
istration of tedizolid phosphate in a single daily dose.33,37,38 
Moreover, only modest accumulation of ∼30% tedizolid was 
observed in the studies that evaluated the administration of 
multiple doses of tedizolid phosphate, which would justify 
its safety profile.33,43
Tedizolid is mostly eliminated in the feces; the urine 
is a minor elimination route. Two studies in healthy adults 
showed that less than 1% of the tedizolid phosphate dose 
administered was eliminated in urine unchanged or as 
tedizolid.37,38 Similarly, in a study in which a single dose of 
radioactively labeled tedizolid phosphate was administered 
to healthy adults, only 18% of the radioactive dose was 
recovered from the urine, whereas 81.5% was recovered 
from the feces.36 In both cases, the greatest metabolite was 
the sulfate analog, 10% or which was present in the urine 
and 69% in the feces.36 N-demethylation and oxidation were 
minor elimination routes.
Three-stage hierarchical population pharmacokinetic 
modeling yielded the following estimations: geometric mean 
clearance of 8.28 L/hour (between-patient variability, 32.3%), 
a volume of the central compartment of 71.4 L (24.0%), and 
a volume of the peripheral compartment of 27.9L (liters) 
(35.7%) in patients with skin and soft tissue infections.40
Special populations
As mentioned, tedizolid phosphate is eliminated via 
the urine to a lesser extent and its pharmacokinetics is 
unchanged in subjects with severe renal impairment. 
Therefore, it is not necessary to adjust this drug in patients 
with reduced renal function.44 Likewise, the pharmacoki-
netics of tedizolid phosphate was not significantly altered 
in subjects with moderate to severe hepatic impairment,45 
so dose adjustments should not be necessary in this patient 
population either.
In a recently completed Phase I clinical trial that com-
pared tedizolid pharmacokinetics following oral admin-
istration of 200 mg tedizolid phosphate in young patients 
(18–45 years) with elderly patients (.65 years), no changes 
were observed.46 In another study, the pharmacokinetic pro-
file of a single oral or IV administration of 200 mg tedizolid 
phosphate to healthy adolescents (12–17 years) was similar 
to that observed in adults.47
Pharmacodynamics
The pharmacodynamic characteristics of tedizolid phosphate 
were evaluated in a study comparing the efficacy of the dose 
fractionation of tedizolid phosphate in a neutropenic mouse-
thigh model of methicillin-sensitive S. aureus (MSSA) and 
MRSA infections.34 The total tedizolid phosphate doses were 









 ratios of free drug were 
calculated for daily doses of tedizolid phosphate of 10, 20, 
36, and 72 mg/kg/24 hours, fractionated into one, two, or 
four times daily. According to the results, the AUC/MIC
0–24 h
 
pharmacodynamic ratio obtained the best correlation with 
the efficacy of tedizolid (r2:0.984). The value of this ratio 
was 45 (22.5/0.5) for a tedizolid phosphate regimen of 
200 mg daily on day 15 of treatment in healthy volunteers, 
which was higher than the value observed with linezolid 
(108.9/4:27.3).37
Spectrum of activity
In general, tedizolid shows excellent activity against aerobic 
Gram-positive microorganisms, including linezolid-resistant 
strains. In contrast, its use in Gram-negative infections is 
limited, given the high MIC of the antibiotic against these 
microorganisms.
Although the clinical breakpoints for tedizolid have not 
yet been defined, the objective of one study was to provide 
some conservative disc diffusion and MIC cut-off values for 
tedizolid (Table 3).48 In general, an MIC of #2 mcg/mL was 
used as the cut-off point of sensitivity.
Aerobic Gram-positive microorganisms
The activity of tedizolid in vitro has been found to be greater 
than that of linezolid against strains of Staphylococcus spp., 
Streptococcus spp., and Enterococcus spp., including strains 
resistant to linezolid and strains not susceptible to vancomy-
cin or daptomycin (Table 4).31,48–55
In a Spanish study, it was observed that the minimum 
inhibitory concentration required to inhibit the growth of 50% 
of organisms (MIC
50
) and minimum inhibitory concentration 
required to inhibit the growth of 90% of organisms (MIC
90
) 
of tedizolid, linezolid, daptomycin, and vancomycin against 
MRSA strains from blood cultures were 0.25 and 0.50 mcg/
mL, 2 and 4 mcg/mL, 0.5 and 0.5 mcg/mL, and 1 and 2 mcg/
mL, respectively.49 In another study, the MIC of tedizolid ranged 
from 0.12 mcg/mL to 0.50 mcg/mL (MIC
90
 of 0.25 mcg/mL) 
against S. aureus strains from skin and soft tissue infections.40 
Similar results were reported in another study in S. aureus 
strains from skin and soft tissue infections, in which the MIC
50
 




Tedizolid phosphate in acute bacterial skin infections
Drug Design, Development and Therapy 2013:7
and MIC
90
 of tedizolid were 0.25 mg/L, regardless of whether 
the isolated strain showed resistance to methicillin.55 These 





 of 1 and 2 mg/L, respectively).
Similarly, tedizolid has shown excellent in vitro activity 
against 28 clinical strains of penicillin-resistant  Streptococcus 





 values of 0.25 mcg/mL.56 These values were 





of 0.5 mcg/mL and 1.0 mcg/mL, respectively). In another 
study, the MIC of tedizolid did not exceed the value of 0.25 
and 0.12 mcg/mL against strains of Streptococcus agalactiae 




 of tedizolid was between two and four 
times lower than that observed with linezolid against strains 
of enterococci (MIC
90
 of 1.0 mcg/mL and MIC
90
 of 0.5 mcg/
mL against strains of enterococci sensitive and resistant to 
vancomycin, respectively).50
Strains resistant to linezolid (non-characterized 
resistance mechanisms)
Tedizolid has shown a high potency against strains of Gram-
positive microorganisms resistant to linezolid (Table 4).48,49,51–53 
The MIC of tedizolid was #4 mcg/mL, #8 mcg/mL, 
and #16 mcg/mL in 88%, 96% and .99% of 120 strains 
not sensitive to linezolid (72 strains of Enterococcus spp. 




 of 2 mcg/mL for tedizolid has been reported 
against strains of S. aureus resistant to linezolid.51 In another 
study, the MIC of tedizolid was 0.5 mcg/mL against seven 
strains of MRSA (MIC against linezolid of 16 mcg/mL) 
and between 0.25 and 4.00 mcg/mL against five strains of 
coagulase-negative staphylococci from blood culture (MIC 
range of linezolid: 16–256 mcg/mL).49 Similar results have 
been obtained in other studies.51,52 In one of them, tedizolid 
showed an activity between eight and 16 times greater than 
linezolid against strains of Staphylococcus spp. resistant to 
linezolid, of which five strains of S. aureus also proved to 
be resistant to vancomycin and another five strains of the 
same species were not sensitive to daptomycin.51 Similarly, 
tedizolid has shown an activity eight times greater than 
linezolid against strains of Enterococcus spp. resistant to 
linezolid.51
Despite the fact that tedizolid shows greater activ-
ity than vancomycin against strains of Gram-positive 
microorganisms resistant to linezolid,53,54 the activity of 
glycopeptide has been shown to be greater in vitro against 
40 strains of coagulase- negative staphylococci and one 
strain of Streptococcus oralis (MIC of vancomycin 1–2 
mcg/mL vs MIC of tedizolid 1 to .32 mcg/mL, MIC of 
vancomycin 0.5 mcg/mL vs MIC of tedizolid 2 mcg/mL, 
respectively).53
Strains with characterized linezolid-resistance 
mechanisms
Tedizolid has maintained its activity against Gram-positive 
microorganisms with characterized resistance mechanisms 
against linezolid (Table 5).51 Thus, tedizolid’s potency has 
been observed to be between eight and 16 times greater 
than that of linezolid in strains of S. aureus that carry the 
G2576U51 mutation (MIC of tedizolid 2–8 mcg/mL vs MIC 
of linezolid 16–64 mcg/mL), and approximately 16 times 
greater in strains of S. aureus which carry the cfr gene 
(MIC of tedizolid 0.5–1.0 mcg/mL vs MIC of linezolid 
8–32 mcg/mL).
Another study reported MIC values for tedizolid of 
between 0.5 and 16.0 mcg/mL when it was tested against 
39 strains of Staphylococcus spp. carrying the G2576U 
mutation (MIC of linezolid 8 to .32 mcg/mL) and between 
0.5 and 8.0 mcg/mL when tested against four strains of 
 Staphylococcus spp.  carrying the cfr gene (MIC of linezolid 
8 to .32 mcg/mL).53 Similarly, the MIC of tedizolid was 
Table 3 Proposed minimum inhibitory concentration (MIC) cut-off point and disc diffusions for tedizolid48
Microorganism Cut-off points (S)
MIC (mcg/mL) Disc diffusion using a disc of 20 or 10 mcg
Staphylococcus aureus #2 $18
Coagulase-negative staphylococci #2 $18
Enterococcus spp., Streptococcus pneumoniae,  
and Streptococcus spp. other than S. pneumoniae
#2 $15 mm
Corynebacterium jeikeium #2 No range recommended due to the reduced 
number of strains tested
Listeria monocytogenes #2 $15 mm
Abbreviation: S, sensitive.
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Table 4 Activity of tedizolid (TR-700) and other antibiotics against Gram-positive microorganisms
Microorganism Strains tested (n) Antibiotic MIC50 (mcg/mL) MIC90 (mcg/mL) Range (mcg/mL)
Corynebacterium jeikeium 1248 Tedizolid 0.25 0.5 0.25–0.50
Cefotaxime 32 32 8–32
Levofloxacin .16 .16 16 .16
Linezolid 1 1 0.5–1.0
Enterococcus faecalis  
S to vancomycin
5448 + 7350 + 4954 TR-70048,50,54 0.25–0.50 0.5–1.0 0.12–1.0
Linezolid48,50,54 2 2 0.5–4.0
vancomycin50,54 1–2 2 0.5–4.0
Cefotaxime48 .64 .64 0.25 . 64.0
Levofloxacin48,54 1–2 .16–64 0.5–64.0
Ampicillin54 1 4 0.25–8.0
Erythromycin54 4 .128 0.12 to .128.0
Tetracycline54 64 64 0.5–128.0
Teicoplanin54 0.25 0.5 #0.12–0.50
E. faecalis R to vancomycin 4548 + 4950 + 1254 TR-70048,50,54 0.25–0.5 0.5 0.25–1.0
Linezolid48,50,54 1–2 1–2 0.5–4.0
vancomycin50,54 .32 to .128 .32 to .128 4 to .128
Cefotaxime48 .64 .64 0.25 to .64.0
Levofloxacin48,54 .16–64 .16–64 0.5–128.0
Ampicillin54 2 4 1–4
Erythromycin54 .128 .128 .128
Tetracycline54 32 64 0.5–64.0
Teicoplanin54 64 64 32–128
E. faecalis R to linezolid 1651 + 1253 TR-70051,53 2–4 4 0.5–8.0
Linezolid51 32 32 8–32
vancomycin51 1 .16 1 to .16
Enterococcus faecium  
S to vancomycin
5248 + 5350 + 3054 TR-70048,50,54 0.25–0.5 0.25–1 0.06–2.00
Linezolid48,50,54 2 2–4 0.5–4.0
vancomycin50,54 0.5–1.0 0.5–1.0 0.25–4.00
Cefotaxime48 .64 .64 0.5 to .64
Levofloxacin48,54 4–64 .16–64 0.5–128.0
Ampicillin54 .128 .128 1 to .128
Erythromycin54 .128 .128 0.25 to .128.00
Tetracycline54 0.5 1 0.12–32.00
Teicoplanin54 0.5 0.5 0.25–2.00
E. faecium R to vancomycin 5248 + 5150 + 2954 TR-70048,50,54 0.12–0.5 0.25–0.5 0.06–2.00
Linezolid48,50,54 1–2 1–4 0.5 to .8.0
vancomycin50,54 .32–128 .32 to .128 8 to .128
Cefotaxime48 .64 .64 .64
Levofloxacin48,54 .16–64 .16–128 1–128
Ampicillin54 .128 .128 64 to .128
Erythromycin54 128 .128 64 to .128
Tetracycline54 0.25 128 #0.06–128.00
Teicoplanin54 16 64 2–64
E. faecium R to linezolid 3651 + 4553 TR-70051,53 2 2–4 0.5–8.0
Linezolid51 32 64 4 to .128
vancomycin53 .16 .16 0.5 to .16
Listeria monocytogenes 3348 Tedizolid 0.25 0.25 0.25–0.50
Cefotaxime 32 32 2–32
Levofloxacin 1 1 1–2
Linezolid 2 2 2–2
Staphylococcus aureus S  
to methicillin
10548 + 9550 + 3054 TR-70048,50,54 0.25–0.50 0.5 0.25–8.00
Linezolid48,50,54 2–4 2–4 1 to .8
vancomycin48,50,54 0.5–1.0 1 0.25–2.00
Oxacillin48,50,54 0.25–0.50 0.5 0.06–0.50
(Continued)
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Table 4 (Continued)
Microorganism Strains tested (n) Antibiotic MIC50 (mcg/mL) MIC90 (mcg/mL) Range (mcg/mL)
Cefotaxime48 2 2 0.03–4.00
Levofloxacin48,54 0.25–0.50 1–4 0.12 to .16.00
Erythromycin48,54 0.5 .128 0.5 to .128.0
Clindamycin48,54 0.25 0.25 #0.06–1.00
Cotrimoxazole48,54 0.25 2 #0.06–32.00
Gentamycin48,54 0.5 128 0.06 to .128.00
Tetracycline48,54 0.5 32 0.25–64.00
S. aureus S to methicillin** 3955 Tedizolid 0.25 0.25 0.12–0.50
Linezolid 1 2 0.5–2.0
S. aureus R to methicillin 12948 + 10350 + 3054 TR-70048,50,54 0.5 0.5–1.0 0.12–16.0
Linezolid48,50,54 2 4 1 to .8
vancomycin50 1 1 0.5–2.0
Oxacillin50,54 32 to .128 32 to .128 4 to .128
Cefotaxime48 16 .64 2 to .64
Levofloxacin48,54 8–16 .16 to .128 0.12 to .128.00
Erythromycin48,54 .128 .128 0.5 to .128.0
Clindamycin48,54 .128 .128 0.25 to .128.00
Cotrimoxazole48,54 0.5 .128 0.25 to .128.00
Gentamycin48,54 64 .128 0.25 to .128.00
Tetracycline48,54 64 64 0.5–128.0
S. aureus R to methicillin  
community-acquired
10050 TR-700 0.5 0.5 0.25–1.00
Linezolid 2 4 1–4
vancomycin 4 4 1–4
Oxacillin 32 32 4 to .32
S. aureus R to methicillin** 12455 Tedizolid 0.25 0.25 0.12–0.50
Linezolid 1 2 0.5–2.0
S. aureus S to linezolid* 44949 TR-700 0.25 0.5 0.125–0.500
Linezolid 2 2 #0.25–4.00
Daptomycin 0.25 0.5 #0.125–1.000
vancomycin 1 1 #0.5–4.0
Teicoplanin #0.5 1 #0.5–4.0
–S. aureus S to linezolid,  
S to oxacillin*
20249 TR-700 0.25 0.25 0.125–0.500
Linezolid 1 2 #0.25–4.00
Daptomycin 0.25 0.5 #0.125–1.000
vancomycin 1 1 #0.5–2.0
Teicoplanin #0.5 1 #0.5–2.0
–S. aureus S to linezolid,  
R to oxacillin*
24749 TR-700 0.25 0.5 0.125–0.500
Linezolid 2 4 #0.25–4.00
Daptomycin 0.5 0.5 #0.125–1.000
vancomycin 1 2 #0.5–4.0
Teicoplanin #0.5 1 #0.5–4.0
S. aureus R to linezolid* 749 TR-700 0.5 NA 0.5
Linezolid 16 NA 16
Daptomycin 0.5 NA 0.5
vancomycin 2 NA 1–2
Teicoplanin 1 NA #0.5–2.0
S. aureus R to linezolid 1348 + 1751 + 552 Tedizolid48,51,52 0.25–4.00 0.2–8.0, NA52 0.12–16.00
Cefotaxime48 .64 .64 2 to .64
Levofloxacin48 .16 .16 0.25 to .16.00
Linezolid48,51,52 2 to .8 .8–16, NA52 1–64
vancomycin52 1 NA 1
Teicoplanin52 1 NA #0.5–2.0
Daptomycin52 0.5 NA 0.5
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Table 4 (Continued)
Microorganism Strains tested (n) Antibiotic MIC50 (mcg/mL) MIC90 (mcg/mL) Range (mcg/mL)
Ciprofloxacin52 .4 NA #1 to .4
Cotrimoxazole52 #1 NA #1
Tetracycline52 #4 NA #4
Erythromycin52 .4 NA #0.5 to .4.0
Clindamycin52 .4 NA .4
Chloramphenicol52 .32 NA 16 to .32
Gentamycin52 #4 NA #4 to .16
Tobramycin52 .16 NA #4 to .16
Rifampicin52 #1 NA #1 to .4
S. aureus not S to vancomycin 3248 Tedizolid 0.25 1 0.12–1.00
Cefotaxime .64 .64 2 to .64
Levofloxacin 16 .16 4 to .16
Linezolid 2 4 1–4
Coagulase-negative staphylococci** 755 Tedizolid NA NA 0.12–0.25
Linezolid NA NA 0.5–1.0
Coagulase-negative  
staphylococci S to linezolid*
199a,49 TR-700 0.25 0.25 #0.03–0.50
Linezolid 1 2 #0.25–4.00
Daptomycin 0.25 0.5 #0.125–1.000
vancomycin 2 2 #0.5–4.0
Teicoplanin 2 8 #0.5–32.0
–Coagulase-negative staphylococci 
S to linezolid, S to oxacillin*
4149 TR-700 0.25 0.25 0.06–0.25
Linezolid 1 2 #0.25–2.00
Daptomycin 0.25 0.5 #0.125–0.500
vancomycin 2 2 #0.5–2.0
Teicoplanin 2 4 #0.5–8.0
–Coagulase-negative staphylococci S 
to linezolid, R to oxacillin*
15849 TR-700 0.125 0.25 #0.03–0.50
Linezolid 1 2 #0.25–4.00
Daptomycin 0.25 0.5 #0.125–1.000
vancomycin 2 2 #0.5–4.0
Teicoplanin 2 8 #0.5–32.0
Coagulase-negative staphylococci  
R to linezolid
5b,49 TR-700 2 NA 0.25–4.00
Linezolid 16 NA 16–256
Daptomycin 0.5 NA 0.25–0.50
vancomycin 2 NA 1–2
Teicoplanin 4 NA 1–16
Coagulase-negative staphylococci  
S to methicillin
4648 + 2954 Tedizolid48,54 0.25–0.50 0.5 0.12–1.0
Cefotaxime48 0.5 2 0.03–4.00
Levofloxacin48,54 0.25–0.50 0.5 0.06–32.00
Linezolid48,54 1–2 2–4 0.5–4.0
Erythromycin54 0.5 128 0.25 to .128.00
Clindamycin54 0.25 1 0.12 to .128.00
Cotrimoxazole54 0.25 16 #0.06–32.00
Gentamycin54 0.12 64 0.06–128.00
Tetracycline54 0.5 32 0.5–128.0
Oxacillin54 0.12 0.25 0.06–0.25
vancomycin54 1 1 0.5–2.0
Coagulase-negative staphylococci  
R to methicillin
5848 + 2654 Tedizolid48,54 0.25–0.50 0.5 0.12–1.00
Cefotaxime48 8 .64 0.5 to .64.0
Levofloxacin48,54 0.5–8.0 $16 0.12 to .16.00
Linezolid48,54 1–2 2–4 0.5–8.0
Erythromycin54 64 128 #0.06 to .128.00
Clindamycin54 0.25 .128 0.12 to .128.00
Cotrimoxazole54 2 32 #0.06–32.00
Gentamycin54 16 64 0.06–128.00
(Continued)
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Table 4 (Continued)
Microorganism Strains tested (n) Antibiotic MIC50 (mcg/mL) MIC90 (mcg/mL) Range (mcg/mL)
Tetracycline54 4 128 0.5 to .128.0
Oxacillin54 4 64 0.5 to .128.0
vancomycin54 1 2 0.25–2.00
Coagulase-negative staphylococci 
not S to linezolid
40c,53 TR-700 4 16 1 to .32
vancomycin 2 2 1–2
Coagulase-negative staphylococci  
R to linezolid
6d,51 + 164e,52 TR-70051,52 NA,51 452 NA,51 852 0.06–16.00
Linezolid51,52 NA,51 12852 NA,51 .12852 8 to .128
vancomycin52 2 4 1–4
Teicoplanin52 4 16 #0.5–64
Daptomycin52 0.5 1 0.25–2.00




Ciprofloxacin52 .4 .4 #1 to .4
Cotrimoxazole52 .4 .4 #1 to .4
Tetracycline52 #4 #4 #4 to .16
Erythromycin52 .4 .4 #0.5 to .4.0
Clindamycin52 .4 .4 #0.5 to .4.0
Chloramphenicol52 .32 .32 #8 to .32
Gentamycin52 .16 .16 #4 to .16
Tobramycin52 .16 .16 #4 to .16
Rifampicin52 .4 .4 #1 to .4
Staphylococcus epidermidis  
S to methicillin
4850 TR-700 0.25 0.5 0.12–1.00
Linezolid 1 2 0.5–4.0
vancomycin 2 2 1–4
Oxacillin 0.12 0.25 0.06–0.25
S. epidermidis R to methicillin 7250 TR-700 0.25 0.5 0.12–1.00
Linezolid 1 2 0.5–4.0
vancomycin 2 2 0.25–4
Oxacillin 16 .32 0.5 $ 32
S. epidermidis R to linezolid 1951 TR-700 4 8 2 to .64
Linezolid 32 .128 16 to .128
Beta-hemolytic streptococci 202f,48 Tedizolid 0.25 0.25 0.12–0.5
Cefotaxime 0.03 0.06 0.015–0.06
Levofloxacin 0.5 1 0.25–2.00
Linezolid 1 2 1–4
Streptococcus agalactiae 5250 + 1554 TR-70050,54 0.25 0.5 0.06–1.00
Linezolid50,54 2 2 1–2
vancomycin50 0.5 0.5 0.25–1.00
Penicillin G54 0.06 0.06 0.03–0.06
Cefotaxime54 0.06 0.06 0.03–0.06
Clindamycin54 0.25 .128 0.25 to .128.00
Erythromycin54 0.5 .128 0.25 to .128.00
Levofloxacin54 1 2 1–2
Streptococcus pneumoniae  
S to penicillin
5348 + 3850 TR-70048,50 0.25 0.25 0.03–0.50
Linezolid48,50 1 1–2 0.12–2.00
vancomycin50 0.25 0.5 0.12–1.00
Cefotaxime48 0.015 0.03 0.015–0.250
Levofloxacin48 1 1 0.25–4.00
S. pneumoniae I to penicillin 2648 + 3750 TR-70048,50 0.25 0.25–0.50 0.06–0.50
Linezolid48,50 1 1–2 0.5–4.0
vancomycin50 0.25 0.5 0.25–0.50
Cefotaxime48 0.12 0.5 0.03–1.00
Levofloxacin48 1 1 0.5–1.0
(Continued)
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Table 4 (Continued)
Microorganism Strains tested (n) Antibiotic MIC50 (mcg/mL) MIC90 (mcg/mL) Range (mcg/mL)
S. pneumoniae R to penicillin 5448 + 3550 TR-70048,50 0.25 0.25 0.06–0.50
Linezolid48,50 1 1–2 0.25–2.00
vancomycin50 0.25 0.5 0.12–1.00
Cefotaxime48 1 8 0.5–8.0
Levofloxacin48 1 1 0.5–2.0
Streptococcus pyogenes 10250 + 1554 TR-70050,54 0.12–0.25 0.25–0.50 0.06–0.50
Linezolid50,54 1 2 0.06–2.00
vancomycin50 0.5 0.5 0.25–1.00
Penicillin G54 0.015 0.015 #0.008–0.015
Cefotaxime54 0.015 0.03 #0.008–0.030
Clindamycin54 0.12 0.25 0.12–0.25
Erythromycin54 0.12 0.25 0.12–0.25
Levofloxacin54 1 4 0.5–4
Streptococcus viridans 3048 Tedizolid 0.25 0.25 0.06–0.50
Cefotaxime 0.12 0.5 0.015–2.000
Levofloxacin 1 2 0.25–2.00
Linezolid 2 2 0.5–2.0
Notes: *Blood culture strains; **skin and skin-structure infection strains; aStaphylococcus epidermidis: 135, Staphylococcus hominis: 40, Staphylococcus haemolyticus: 
19, Staphylococcus lugdunensis: 3, Staphylococcus intermedius: 1, Staphylococcus warneri: 1; bS. epidermidis: 2, S. hominis: 2, S. haemolyticus: 1; cStaphylococcus capitis: 2, S. 
epidermidis: 29, S. haemolyticus: 5, Staphylococcus simulans: 2, Staphylococcus xylosus: 2; dS. hominis: 1, Staphylococcus sciuri: 5; eS. epidermidis: 142, S. hominis: 15, S. warneri: 
7; fStreptococcus agalactiae: 101, Streptococcus pyogenes: 101. In bold: Staphylococcus aureus S to linezolid* group includes 202 strains of S. aureus S to linezolid, S to 
oxacillin* and 247 strains of S. aureus S to linezolid, R to oxacillin*. Coagulase-negative staphylococci S to linezolid* group includes 41 strains of coagulase-negative 
staphylococci S to linezolid, S to oxacillin* and 158 strains of coagulase-negative staphylococci S to linezolid, R to oxacillin*. Data from Brown and Traczewski,48 Betriu 
et al,49 Schaadt et al,50 Shaw et al,51 Rodríguez-Avial et al,52 Jones et al,53 Yum et al,54 Prokocimer et al.55
Abbreviations: S, sensitive; I, intermediate sensitivity; R, resistant; NA, not applicable; MIC50, minimum inhibitory concentration required to inhibit the growth of 50% of 
organisms; MIC90, minimum inhibitory concentration required to inhibit the growth of 90% of organisms.
between 2 and 4 mcg/mL against seven strains of Enterococ-
cus faecium and one strain of Enterococcus faecalis carrying 
the G2576U mutation, compared with an MIC for linezolid 
of between 16 and 32 mcg/mL.51 Another study reported MIC 
values for tedizolid between 0.5 and 8.0 mcg/mL when tested 
against 69 strains of Enterococcus spp. carrying the G2576T 
mutation (MIC of linezolid 4 to .32 mcg/mL).53
In another study, resistance to tedizolid was observed in 
only three of the 36 strains of Enterococcus spp. resistant 
to linezolid analyzed.57 Two of them were strains of E. fae-
cium homozygous for the G2576T mutation (MIC against 
tedizolid of 8 mcg/mL), while no resistance mechanism 
could be established in the third strain of this same species 
(MIC against tedizolid of 16 mcg/mL).
Aerobic Gram-negative microorganisms
Tedizolid shows a limited activity against strains of 
 Haemophilus influenzae and Moraxella catarrhalis (MIC
90
 of 
16 and 4 mcg/mL, respectively) (Table 6).50 Both tedizolid 
and linezolid have shown a lower activity than that of cefo-
taxime and levofloxacin against strains of these microorgan-
isms.48 However, the MIC
90
 of tedizolid was two times lower 
than that observed for linezolid (MIC
90
 for linezolid of 32 
and 8 mcg/mL, respectively).50
Anaerobic microorganisms
The activity of tedizolid against anaerobic microorganisms 
has been reported to be greater than or equal to that observed 
with linezolid (Table 7).50
Acid-fast bacilli
Tedizolid has shown excellent activity against 95 strains of 
Mycobacterium tuberculosis, nine of which showed resistance 
to isoniazid or rifampicin and 25 to both  tuberculostatics.58 
The MIC
50
 was 0.25 mcg/mL and the MIC
90
 was 0.50 mcg/mL 





of tedizolid phosphate were 0.5 mcg/mL against ten strains 
of sensitive M. tuberculosis and ten strains of M. tuberculosis 
resistant to tuberculostatics.
Resistance mechanisms
Several oxazolidinone resistance mechanisms have been 
described, including mutations in domain V of 23S rRNA59,60 
and horizontal transmission of the cfr gene.17,18 However, 
a number of ribosomal proteins of the 50S subunit have regions 
that interact with the oxazolidinone-binding site in the peptidyl 
transferase center, most notably L3 and L4. Mutations in the 
genes that encode these proteins may have an impact on the 
sensitivity presented by different microorganisms to this family 
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Table 5 Activity of tedizolid (TR-700) and other antibiotics against Gram-positive microorganisms with characterized linezolid-
resistance mechanisms
Microorganism Strains tested (n) Antibiotic MIC50 (mcg/mL) MIC90 (mcg/mL) Range (mcg/mL)
G2576T
Enterococcus spp. 69a,53 TR-700 2 2 0.5–8
Linezolid 8 16 4–32
Ciprofloxacin .4 .4 1 to .4
Daptomycin 1 2 0.12–4.00
Erythromycin .2 .2 #0.25 to .2.0
Quinupristin/dalfopristin 1 .2 #0.25 to .2.0
Teicoplanin .16 .16 #0.12 to .16.00
Tetracycline #2 .8 #2 to .8
vancomycin .16 .16 0.5 to .16.0
Staphylococcus spp. 39b,53 TR-700 4 8 0.5–16.0
Linezolid 16 .32 8 $ 32
Ciprofloxacin .4 .4 0.25 to .4.00
Clindamycin 1 .2 #0.25 to .2.00
Daptomycin 0.25 0.5 0.25–1.00
Erythromycin .2 .2 #0.25 to .2.00
Gentamicin .8 .8 #2 to .8
Oxacillin .2 .2 #0.25 to .2.00
Quinupristin/dalfopristin 0.5 1 #0.25–2.00
Teicoplanin 4 8 0.5–16.0
Tetracycline #2 .8 #2 to .8
Trimethoprim/sulfamethoxazole .2 .2 #0.5 to .2.0
vancomycin 2 2 0.5–2.0
crf gene
Staphylococcus spp. 4c,53 TR-700 1 – 0.5–8.0
Linezolid 32 – 8 to .32
Ciprofloxacin .4 – .4
Clindamycin .4 – .4
Daptomycin #0.25 – #0.25
Erythromycin #0.25 – #0.25 to .2.00
Gentamicin .8 – #2 to .8
Oxacillin .2 – .2
Quinupristin/dalfopristin .2 – 1 to .2
Teicoplanin #2 – #2
Tetracycline #2 – #2 to .8
Trimethoprim/sulfamethoxazole .2 – #0.5 to .2.0
vancomycin 1 – 1–2
Notes: aEnterococcus faecalis: 15, Enterococcus faecium: 54; bStaphylococcus aureus: 6, Staphylococcus epidermidis: 22, Staphylococcus capitis: 2, Staphylococcus haemolyticus: 
5, Staphylococcus simulans: 2, Staphylococcus xylosus: 2; cS. aureus: 2, S. epidermidis: 2.
Data from Jones et al.53
Abbreviations: MIC50, minimum inhibitory concentration required to inhibit the growth of 50% of organisms; MIC90, minimum inhibitory concentration required to inhibit 
the growth of 90% of organisms.
of antibiotics. L3 mutations were first associated with reduced 
susceptibility to oxazolidinones in a study that sequenced the 
rplC gene, encoding L3, in eleven clinical isolates resistant 
to linezolid.61 The sequence analysis identified two L3 muta-
tions, ∆Ser145 in S. aureus strain NRS127 and Ala157Arg in 
Staphylococcus epidermidis strain 1653059, both adjacent to 
the oxazolidinone-binding site in the peptidyl transferase cen-
ter. Tedizolid maintained an eight- to 16-fold potency advan-
tage over linezolid against strains NRS127 (MIC 1 vs 8 mcg/
mL) and 1653059 (MIC 16 vs 256 mcg/mL). Another study 
of MRSA clinical isolates resistant to linezolid and carrying 
the cfr gene identified mutations in L3, including ∆Ser145/
His146Tyr and ∆Met169-Gly174.62 The MICs of tedizolid 
were between 1 and 2 mcg/mL, while those of linezolid were 
between 32 and 64 mcg/mL, respectively.
A study analyzed the structure–activity relationship of 
different oxazolidinones against strains of S. aureus resistant 
to linezolid due to ribosomal mutations (23S rRNA, L3, L4) 
or due to methylation of 23S rRNA via horizontal transfer of 
the cfr gene.63 According to the MIC values observed in this 
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Table 6 Activity of tedizolid and other antibiotics against Gram-negative microorganisms
Microorganism Strains tested (n) Antibiotic MIC50 (mcg/mL) MIC90 (mcg/mL) Range (mcg/mL)
All Haemophilus influenzae 9948 + 2554 Tedizolid48,54 2–8 4–16 2–32
Cefotaxime48,54 0.015–0.030 0.5 #0.008–2.000
Levofloxacin48,54 0.12 0.12 0.12
Linezolid48,54 $8 .8–16 4–16
Ampicillin54 .128 .128 0.5 to .128.0
Ampicillin/sulbactam54 4 8 0.5–8.0
Cefaclor54 4 .128 2 to .128
Cefuroxime54 1 .128 0.25 to .128.0
Azithromycin54 4 4 2–4
Cotrimoxazol54 4 32 #0.06–32.00
Tetraciclina54 0.5 8 0.25–32.00
Beta-lactamase-negative  
H. influenzae
3248 Tedizolid 8 16 4–32
Cefotaxime 0.008 0.015 0.008–0.030
Levofloxacin 0.12 0.12 0.12
Linezolid .8 .8 4 to .8
Beta-lactamase-positive  
H. influenzae
4248 Tedizolid 8 32 4–32
Cefotaxime 0.015 0.015 0.008–0.030
Levofloxacin 0.12 0.12 0.12
Linezolid .8 .8 8 to .8
Beta-lactamase-negative  
H. influenzae, not sensitive  
to ampicillin
2548 Tedizolid 8 16 2–16
Cefotaxime 0.5 0.5 0.03–2.00
Levofloxacin 0.12 0.12 0.12
Linezolid .8 .8 .8 to .8
Moraxella catarrhalis 5048 + 2754 Tedizolid48,54 1–4 1–4 0.5–4
Cefotaxime48 0.250 1 0.03–2
Levofloxacin48,54 0.06 0.06 0.03–0.06
Linezolid48,54 4–8 4–8 2–16
Penicillin G54 16 32 0.03–32
Cefaclor54 2 8 0.25–32
Clindamycin54 2 4 1–4
Erythromycin54 0.25 0.5 0.12–0.5
Tetracycline54 0.5 0.5 0.25–16
Data from Brown and Traczewski48 and Yum et al.54
Abbreviations: MIC50, minimum inhibitory concentration required to inhibit the growth of 50% of organisms; MIC90, minimum inhibitory concentration required to inhibit 
the growth of 90% of organisms.
study, the C and D rings play a fundamental role in the activity 
of the antimicrobial, both in strains with ribosomal mutations 
and in strains that carry the cfr gene. As has been suggested 
previously, the C and D rings of the tedizolid molecule may 
act as additional hydrogen bond donors to the sugar backbone 
of residues A2451 and U2584 of rRNA.51  Furthermore, the 
presence of both 1,2,3-triazole and hydroxymethyl substitu-
ents on C-5 of ring A maintained the potency of the antibiotic 
against strains carrying the cfr gene, while the presence of 
acetamide substituents was associated with a fourfold increase 
in the MIC value of the antimicrobial.63
The structure of linezolid does not contain the D ring and 
has an acetamide substituent on C-5 of ring A, unlike tedizolid, 
whose structure contains a D ring and a hydroxymethyl sub-
stituent on C-5 of ring A. These structural features explain why 
tedizolid maintains activity against strains with high MICs of 
linezolid, especially those strains that carry the cfr gene. In the 
same study, the S. aureus MIC values of tedizolid were 0.5 to 
1.0 mcg/mL against strains carrying ribosomal mutations (vs 
2 to 32 mcg/mL for linezolid) and 0.5 mcg/mL against all cfr-
positive strains tested (vs 2 to 16 mcg/mL for linezolid).63
The potential for S. aureus to develop resistance to tedi-
zolid was investigated in a study using representative MSSA 
and MRSA strains through determination of spontaneous 
mutation frequencies and by serial passage on antibiotic 
gradient plates containing tedizolid or linezolid.64 The median 
spontaneous mutation frequency that resulted in a reduction 
in sensitivity to tedizolid was 1.1 × 10-10 for the MSSA 
strain and 1.9 × 10-10 for the MRSA strain. These values 
were approximately 16-fold lower than those obtained for 
linezolid (2.0 × 10-9 for MSSA and 3.0 × 10-9 for MRSA). 
The spontaneous mutant strains selected with tedizolid 
 possessed the T2500A 23S rRNA mutation or Gly155Arg, 
Gly155Arg/Met169 Leu, or ∆Phe127-His146 mutations in 
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Table 7 Activity of tedizolid and other antibiotics against anaerobic microorganisms
Microorganism Strains tested (n) Antibiotic MIC50 (mcg/mL) MIC90 (mcg/mL) Range (mcg/mL)
Bacteroides fragilis 1050 + 3054 TR-70050,54 2–4 2–4 1–4
Linezolid50,54 4 4 2–4
Metronidazole50,54 0.12–4.00 1–4 0.12 to .32.00
Imipenem50,54 0.12–0.25 0.5–1.0 #0.06–4.00
Ampicillin54 32 .128 16 to .128
Ampicillin/sulbactam54 2 16 1–32
Piperacillin54 32 256 4 to .256
Piperacillin/tazobactam54 0.25 1 0.12–8.00
Cefoxitin54 8 32 4–64
Cefotetan54 8 32 4–128
Clindamycin54 128 .128 #0.06 to .128.00
Bacteroides vulgatus 1050 TR-700 2 4 1–8
Linezolid 2 4 2–4
Metronidazole 0.25 0.25 0.12–0.50
Imipenem 0.25 0.5 0.25–0.50
Bacteroides  
thetaiotaomicron
1050 + 1554 TR-70050,54 2 2 1–2
Linezolid50,54 4 4–8 4–8
Metronidazole50,54 1–4 1–4 0.5 to .32
Imipenem50,54 0.25–0.50 1–2 0.12–4
Ampicillin54 32 .128 16 to .128
Ampicillin/sulbactam54 1 32 1–32
Piperacillin54 32 .256 16 to .256
Piperacillin/tazobactam54 4 8 2–16
Cefoxitin54 16 32 16–32
Cefotetan54 128 .128 32 to .128
Clindamycin54 8 .128 2 to .128
Bacteroides ovatus 1050 TR-700 2 8 0.06–8.00
Linezolid 8 8 0.5–8.0
Metronidazole 1 1 0.5 to .32.0
Imipenem 0.25 0.5 0.06–0.50
Clostridium perfringens 1050 + 1554 TR-70050,54 0.25–0.50 0.25–2.0 0.12–2.00
Linezolid50,54 2 2–4 1–2
Metronidazole50,54 1–4 4 to .32 1 to .32
Imipenem50,54 #0.06–0.12 #0.06–0.50 #0.06–1.00
Ampicillin54 #0.06 0.12 #0.06–0.50
Ampicillin/sulbactam54 #0.06 0.25 #0.06–0.50
Piperacillin54 #0.06 0.25 #0.06–1.00
Piperacillin/tazobactam54 #0.06 #0.06 #0.06
Cefoxitin54 0.5 1 0.25–1.00
Cefotetan54 #0.06 0.12 #0.06–0.50
Clindamycin54 1 2 #0.06–2.00
vancomycin54 0.5 0.5 0.5–2.0
Peptostreptococcus spp. 59a,54 Tedizolid 0.06 0.25 0.03–0.25
Linezolid 0.5 1 0.25–2.00
Ampicillin 0.12 1 #0.06–16.00
Ampicillin/sulbactam 0.12 1 #0.06–8.00
Piperacillin #0.06 8 #0.06–16.00
Piperacillin/tazobactam #0.06 8 #0.06–16.00
Cefoxitin 0.25 4 #0.06–16.00
Cefotetan 0.5 16 #0.06–128.00
Imipenem #0.06 0.12 #0.06–1.00
Clindamycin 0.5 64 #0.06 to .128.00
Metronidazole 1 2 #0.06–4.00
vancomycin 0.25 0.5 #0.12–1.00
Peptostreptococcus  
anaerobius
1050 TR-700 0.25 0.5 0.12–0.50
Linezolid 1 2 0.5–8
(Continued)
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Table 7 (Continued)
Microorganism Strains tested (n) Antibiotic MIC50 (mcg/mL) MIC90 (mcg/mL) Range (mcg/mL)
Metronidazole 0.5 1 #0.06–1.00
Imipenem 0.06 1 #0.03–1.00
Peptostreptococcus  
micros
1050 TR-700 0.25 0.5 0.12–1.00
Linezolid 1 2 0.5–2.0
Metronidazole #0.06 .32 #0.06 to .32.00
Imipenem #0.03 #0.03 #0.03 to #0.06
Porphyromonas  
asaccharolytica
1050 TR-700 0.25 0.5 0.25–0.50
Linezolid 1 2 0.5–2
Metronidazole 1 1 0.5–2
Imipenem ,0.03 0.06 #0.03 to #0.06
Prevotella spp. 2050 TR-700 1 4 #0.06–16.00
Linezolid 2 4 0.25–16.00
Metronidazole 0.5 .32 #0.06 to .32.00
Imipenem #0.06 1 #0.03–16.00
Notes: aFinegoldia magna: 19, Peptoniphilus asaccharolyticus: 15, Peptostreptococcus anaerobius: 12, Peptostreptococcus micros: 7, Anaerococcus prevotii: 6.
Data from Schaadt et al50 and Yum et al.54
Abbreviations: MIC50, minimum inhibitory concentration required to inhibit the growth of 50% of organisms; MIC90, minimum inhibitory concentration required to inhibit 
the growth of 90% of organisms.
L3. Linezolid-selected spontaneous mutants possessed the 
T2500A or G2447T 23S rRNA mutations or the Gly155Arg 
or Gly155Arg/Met169 Leu L3 mutations.
Following 30 serial passages on antibiotic gradient 
plates, the MIC of tedizolid against the MSSA strain 
remained at 0.5 mcg/mL whereas the MIC of linezolid 
increased from 2 to 128 mcg/mL. Reduced sensitivity 
to linezolid was observed after five serial passages in a 
medium with linezolid, associated with the Gly155Arg 
mutation in L3. Subsequent passages in this medium 
resulted in mutant strains of MSSA that had the 23S rRNA 
G2447T mutation alone or the G2447T mutation coupled 
with the Gly152Asp mutation in L3. After serial passage of 
the MRSA strain, tedizolid MIC values increased eightfold 
(from 0.25 to 2.00 mcg/mL) while the MIC of linezolid 
increased 32-fold (from 1 to 32 mcg/mL). The reduction 
in sensitivity of the MRSA strain to linezolid was associ-
ated initially with the Lys68Gln mutation in L4 and later 
by the G2576T mutation in 23S rRNA, while resistance to 
tedizolid was associated with a T25761C/G2576T double 
mutation in 23S rRNA.64
A second resistance-selection study passaged eight 
linezolid-susceptible strains through a medium contain-
ing tedizolid. A twofold increase in the MIC of tedizolid 
after 14 days was found in three of the strains: MSSA, 
VanA-phenotype E. faecalis, and S. pyogenes carrying 
the erm(A) gene. All tedizolid MIC values were less than 
or equal to 0.5 mcg/mL at the end of the experiment and 
all returned to baseline following passage in nonselec-
tive media.53
According to the results of the studies described to 
date, tedizolid has a more favorable resistance profile than 
linezolid.53,64
Animal studies
Studies in murine models have evaluated antibacterial activ-
ity, pharmacokinetics, and pharmacodynamic correlates of 
efficacy to determine exposure–response relationships for 
tedizolid. A dose-range study of tedizolid phosphate in a 
neutropenic mouse-thigh model of MSSA and MRSA infec-
tions with linezolid as a comparator, determined that AUC
free
/
MIC is the main determinant of efficacy.34 For MSSA strains, 
the administration of a mean dose of tedizolid phosphate/
tedizolid of 37.7 mg/kg/day resulted in stasis and a mean 
dose of 66.9 mg/kg/day resulted in the reduction of 1 log 
colony-forming unit (CFU)/g at 24 hours. Similarly, the 
administration of a mean dose of tedizolid phosphate/tedizolid 
of 35.3, 46.6, and 71.1 mg/kg/day resulted in stasis, reduction 
of 1 log CFU/g, and reduction of 2 log CFU/g at 48 hours, 
respectively. Additionally, for MRSA strains, the administra-
tion of a mean dose of tedizolid phosphate of 36.2 mg/kg/day 
resulted in stasis and a mean dose of 58.0 mg/kg/day resulted 
in the reduction of 1 log CFU/g at 24 hours. Similarly, the 
administration of a mean dose of tedizolid phosphate of 39.8, 
52.4, and 105.0 mg/kg/day resulted in stasis, reduction of 1 log 
CFU/g and reduction of 2 log CFU/g at 48 hours, respectively. 
There were no differences in the doses of tedizolid phosphate 
needed to reach these values for strains of MSSA and MRSA. 
When compared with linezolid, the administration of doses 
up to 150 mg/kg/day resulted in bacterial densities in the 
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24 hours, 2.13–2.68 log10 at 48 hours, and 2.68–3.72 log10 
at 72 hours, while exposure to linezolid reduced the number 
of CFUs to 1.36–2.02 log10 at 24 hours, 2.19–3.11 log10 
at 48 hours, and 2.64–3.76 log10 at 72 hours. Statistically 
significant differences were observed in the number of CFUs 
for some S. aureus strains at 24, 48, or 72 hours, although 
they were not consistent throughout the study period.
Tedizolid has shown in vitro activity against strains 




 values of 
1 mg/L,58 and both tedizolid and tedizolid phosphate have 
shown a high capacity for inhibiting intracellular growth of 
N. brasiliensis in vitro.68 Therefore, the objective of one study 
was to evaluate the activity of two different doses of tedizolid 
phosphate (5 or 25 mg/kg), in monotherapy or combined 
with trimethoprim/sulfamethoxazole, in a murine model of 
actinomycosis due to N. brasiliensis.69 Linezolid was used 
as a comparator treatment and saline solution as a control. 
At the end of treatment, statistically significant differences 
were observed in the degree of infection between all groups 
that received the different antibiotic treatments and the 
control group (P = 0.004). However, a greater response was 
observed in the groups that received tedizolid phosphate at a 
dose of 25 mg/kg, both in monotherapy and in combination 
with trimethoprim/sulfamethoxazole, than in the groups that 
received the other treatments.
Another study evaluated the activity of tedizolid phos-
phate at doses of 5, 12.5, and 25 mg/kg in a murine model 
of actinomycosis due to N. brasiliensis.70 Saline solution 
was used as a control. The animals received the treatment 
1 week after infection for a period of 3 weeks. Subsequently, 
the treatment was suspended for 1 week and started again for 
another 3 weeks. At the end of treatment, statistically sig-
nificant differences were observed in the degree of infection 
between the control group and the groups that received the 
three doses of tedizolid phosphate (P , 0.001).
One study assessed survival at 7 days in a murine 
model with systemic infection with penicillin-resistant 
S. pneumoniae after administration of tedizolid phosphate 
orally or intravenously at different doses.56 Four strains of 
penicillin-resistant S. pneumoniae were used (DR9, DR10, 
DR11, and DR14) and linezolid was used as a comparator 
treatment. The ED50 of tedizolid phosphate administered 
orally ranged from 5.7 mg/kg/day for the mice infected with 
DR9 to 11.53 mg/kg/day for those infected with DR14. This 
latter value was equivalent to that observed with linezolid, 
while the values compared with the rest of the strains were 
lower. Similarly, the ED50 of tedizolid phosphate administered 
intravenously ranged from 4.89 mg/kg/day in mice infected 
mouse thigh of approximately 1 log CFU/g higher than the 
stasis values.
An in vitro study showed that tedizolid accumulated 
inside the macrophages and reached a ratio of approximately 
10 between the intracellular and extracellular concentration.65 
The value of this ratio was 1–2 for linezolid. Based on this 
finding, the objective of another study was to evaluate the 
effect of granulocytes in the activity of tedizolid in a murine 
model infected with strain 33591 of MRSA compared with 
the same neutropenic infection model.66 It used doses of 
tedizolid phosphate equivalent to those humans would be 
given, ranging from 200 to 3200 mg daily. The animals were 
evaluated at 24, 48, and 72 hours after starting treatment. In 
the animals with a normal immune system, bacteriostasis 
was obtained at an equivalent dose in humans of slightly 
above 100 mg daily after 24 hours and less than 100 mg per 
day at 48-hour and 72-hour endpoints. The dose equivalent 
to 1200 mg given daily in humans obtained the maximum 
response after 24 hours and the dose equivalent to 800 mg 
given daily in humans obtained the maximum response after 
48 hours. Lastly, the dose equivalent to 200 mg adminis-
tered daily in humans produced a near-maximal effect after 
72 hours, with no significant differences observed compared 
with the dose of 3200 mg daily. In contrast, in the neutro-
penic animals, bacteriostasis was achieved using a dose 
equivalent to slightly under 2300 mg given daily in humans 
after 24 hours and a dose slightly under 2000 mg daily after 
72 hours. The dose equivalent to 3200 mg administered in 
humans was associated with maximum response.
Furthermore, a reduction in the colony counts of 
S. aureus strains was observed in immunocompetent mice 
after the administration of a dose equivalent to 200 mg of 
tedizolid phosphate given in humans, whereas an increase 
of 1 log CFU/g was observed in the granulocytopenic 
 animals. This difference revealed that the antibiotic effect 
was  mediated by the granulocytes.66
In another study, the effective dose for 50% of people 
(ED50) value of IV tedizolid phosphate was 2.8 mg/kg in a 
murine model with systemic MRSA infection and 3.3 mg/kg 
when this infection was caused by MSSA, while the ED50 of 
oral tedizolid phosphate was 3.7 mg/kg in the murine model 
with systemic MRSA infection and 5 mg/kg when this infec-
tion was caused by MSSA.31 These values were lower than 
those observed with linezolid. However, no differences were 
observed between the efficacy of tedizolid and linezolid in a 
murine model infected with five strains of S. aureus, four of 
which showed resistance to methicillin.67 Thus, exposure to 
tedizolid reduced the number of CFUs to 1.04–1.80 log10 at 
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with DR9 to 10.19 mg/kg/day for those infected with DR11. 
These values were lower than those observed with linezolid 
against the four strains of penicillin-resistant S. pneumoniae.
Clinical efficacy
To date, there have been a limited number of studies in 
humans evaluating the efficacy of tedizolid phosphate or 
tedizolid in skin and soft tissue infections, and some of these 
are still underway. The objective of one Phase II randomized 
double-blind clinical trial was to evaluate the efficacy of tedi-
zolid phosphate administered at doses of 200, 300, or 400 mg 
once daily for 5–7 days in patients with complicated skin 
and soft tissue infections.40 These included abscesses (with 
at least 2 cm of surrounding induration or requiring incision 
and drainage), surgical or posttraumatic wounds, and deep 
extensive cellulitis. A total of 192 patients were randomized 
between September 2008 and January 2009, of whom 188 
received at least one dose of tedizolid phosphate and these 
188 patients presented with a diagnosis of complicated skin 
and soft tissue infection (modified intent-to-treat and clini-
cal modified intent-to-treat, respectively). Of the 188, 164 
were included in the clinically evaluable population, 154 in 
the microbiological modified intent-to-treat population, and 
133 in the microbiologically evaluable population. S. aureus 
strains were isolated in 139 (90.3%) of the 154 patients in 
whom a baseline Gram-positive microorganism was iso-
lated, of which 80.6% were MRSA. The clinical cure rate 
in clinically evaluable patients was 98.2% for the group that 
received 200 mg of tedizolid phosphate and 94.4% for the 
group that received 300 or 400 mg of the antibiotic; no dif-
ferences were observed in terms of the type and size of the 
lesion or the severity of the infection. Likewise, the clinical 
cure rate in microbiologically evaluable patients in whom S. 
aureus strains (n = 119) had been isolated was 96.6%, reach-
ing a value of 96.8% when the isolated strains were MRSA. 
 Clinical failure was observed in seven patients (3.7%).
In addition, the overall microbiological eradication 
rate was 97.7% in the microbiologically evaluable patients 
(n = 133), with no differences observed in terms of dose. 
This rate ranged from 92.6% to 100% when MRSA strains 
were isolated and from 88.9% to 100% when MSSA strains 
were isolated. Emerging pathogenic microorganisms were 
isolated in 2/188 (1%) patients.
The importance of adequate dosing of tedizolid was 
highlighted in a study that evaluated the production of 
phenol-soluble modulins by S. aureus strains from skin and 
soft tissue infections at different concentrations of the antibi-
otic.71 Tedizolid inhibited the production of these proteins at 
half the MIC concentration, mainly affecting the production 
of phenol-soluble modulin alpha 3 and, to a lesser extent, 
the production of phenol-soluble modulin alpha 4. How-
ever, when the concentration of tedizolid was one-quarter 
and one-eighth of the MIC, it induced the production of 
phenol-soluble modulins, mainly in those strains with a low 
baseline production of phenol-soluble modulin alpha 3. The 
highest increase observed in the phenol-soluble modulin 
alpha 3 concentration was 4.6 from 2.5 mcg/mL.  Similar 
results were obtained with the control strain, increasing the 
phenol-soluble modulin alpha 3 concentration from 3.90 to 
5.43 and 5.63 mcg/mL with tedizolid concentrations at one-
quarter and one-eighth of the MIC value, respectively. This 
study highlights the importance of the adequate dosing of 
these antibiotics with an aim to minimize the potential for 
induction of virulence.
A Phase III randomized double-blind multicenter study 
was carried out to evaluate the efficacy of tedizolid phos-
phate 200 mg daily taken orally for 6 days compared with 
linezolid 600 mg every 12 hours taken orally for 10 days in 
667 patients with acute bacterial skin and soft tissue infec-
tions from North America, South America, and Europe.72 
Tedizolid was not inferior to linezolid when the primary and 
secondary endpoints were evaluated in the intent-to-treat 
analysis.73 Given that the duration of tedizolid treatment was 
4 days fewer than that of linezolid, an additional analysis 
to the previous study was conducted in the 245 patients 
who were diagnosed with cellulitis with a minimum total 
 surface area of the lesion of 75 cm2.74 The US Food and 
Drug  Administration (FDA) endpoint was cessation of lesion 
extension and absence of fever at 48–72 hours, while the 
European Medicines Agency (EMA) endpoint was evalua-
tion of the clinical result by the investigator 7–14 days after 
the end of treatment, both in the intent-to-treat group. The 
FDA endpoint was obtained in 72% (53/74) of the patients 
in the USA and in 82% (37/45) of the patients in Europe who 
received treatment with tedizolid, whereas, in the case of 
linezolid, these values were 69% (55/80) and 76% (35/46), 
respectively. Similarly, the EMA endpoint was obtained in 
82% (61/74) of the patients in the USA and in 98% (44/45) 
of the patients in Europe who received treatment with tedi-
zolid, whereas, in the case of linezolid, these values were 
78% (62/80) and 91% (42/46), respectively. According to 
the results, the cure rate was higher in US and European 
patients who received tedizolid, for both the FDA and EMA 
endpoints.
A second Phase III randomized double-blind multicenter 
study is currently underway with the same objective as the 
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previous study, but is evaluating the transition from IV to oral 
route with both tedizolid phosphate and linezolid.75
Tolerability
Based on the adverse effects described for linezolid, several 
studies have been conducted with tedizolid to ascertain whether 
this molecule improves the toxicity profile of linezolid.
In general, the tolerability of tedizolid phosphate has 
been evaluated in several studies.40,76,77 One of them was 
performed in 40 healthy subjects who received either single 
doses of the antibiotic ranging from 200 to 1200 mg or 
 placebo.76 Twenty-eight treatment-related adverse effects, all 
of mild severity and apparently independent of the dose, were 
reported, including nausea (10%), dizziness (6.7%), diarrhea 
(6.7%), and nasal congestion (6.7%).
In a second study with ten adolescent subjects aged 
between 12 and 17 years, no serious adverse effects were 
observed, nor were there alterations in the electrocardiogram 
or analytical parameters after the administration of a single 
dose of 200 mg tedizolid phosphate.77 Only one patient 
presented with mild abdominal pain related to the tedizolid 
phosphate treatment.
Another study evaluated the tolerability and safety of 
tedizolid treatment at doses of 200, 300, and 400 mg adminis-
tered during a 5–7 day period in 188 adult patients with skin 
and soft tissue infections.40 Adverse effects were reported 
in 69.1% of the patients, of which 24.6% were classified as 
moderate and 72.3% as mild; treatment did not have to be 
interrupted in any case (Table 8). Only 2.7% of the patients 
experienced serious adverse effects, none of which was attrib-
utable to the drug. None of the toxicities was dose- dependent. 
The adverse effects reported by the investigators as treatment-
related included nausea (16.5%), diarrhea (8.5%; Clostridium 
difficile was not isolated in any case), vomiting (6.9%), and 
headache (6.4%). One patient experienced an increase in 
their QT interval of more than 60 ms.
The tolerability of tedizolid in IV infusion was evalu-
ated in ten healthy patients who received an infusion of 
tedizolid phosphate 200 mg in 250 mL of saline solution 
for 60 minutes by peripheral vein for 3 days.78 Each patient 
acted as their own control by receiving placebo in the other 
treatment arm.  Phlebitis was evaluated using the Visual 
Infusion Phlebitis (VIP) scale and good peripheral tolerance 
was demonstrated.
Currently, several studies evaluating the safety profile of 
tedizolid are underway. One of these is a Phase II open-label 
multicenter clinical trial evaluating the tolerability of the 
administration of 200 mg of tedizolid phosphate once daily 
in patients over 18 years of age with skin infections (major 
cutaneous abscesses, erysipelas, and cellulitis).79
In general, the tolerability of tedizolid phosphate is simi-
lar to that observed with linezolid, according to a Phase III 
study that compared the safety profile of the adverse effects 
of treatment with tedizolid phosphate 200 mg once daily for 
6 days or linezolid 600 mg twice daily for 10 days in patients 
with skin and soft tissue infections.73 The results showed a 
drug-related adverse effects rate of 24.2% in the group that 
received tedizolid phosphate compared with 31.0% in the 
group that received linezolid.
One of the greatest concerns with linezolid treatment 
is the potential for developing blood toxicity, including 
anemia, thrombocytopenia, leucopenia, or pancytopenia; an 
association with the duration of antibiotic treatment has been 
observed.80,81 Therefore, weekly complete blood counts are 
recommended, especially in patients who present with prior 
myelosuppression or who receive concomitant myelotoxic 
Table 8 Most common treatment-emergent adverse events 
(.2% of treated subjects) (N = 188)40
Adverse effect(s) N (%)
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drugs,82 and treatment should be discontinued in patients 
who develop this adverse effect. Myelosuppression associated 
with linezolid is one of the main factors that limit its use.
Thus, of great therapeutic advantage would be the 
development of new molecules belonging to the oxazolidi-
none family that maintain antimicrobial activity but have a 
lower hematological toxicity profile. As such, the objective 
of several studies has been to evaluate the hematological 
toxicity of tedizolid phosphate. One study conducted in ani-
mals monitored signs of toxicity after the administration of 
increasing single doses up to 250 mg/kg IV and 2000 mg/kg 
orally in rats and mice of both sexes.83 The toxic effects of 
administration of tedizolid phosphate at doses between 10 
and 100 mg/kg for 4 weeks were also evaluated. The median 
lethal dose ranged from 244 and 274 mg/kg for the IV route 
and 2000 and 2052 mg/kg for the oral route.
The repeat-dose no observed adverse effect level was 
30 mg/kg for males and 10 mg/kg for females and the toxic-
ity target organs were both the lymphatic and hematopoietic 
organs, such as the spinal cord, thymus, spleen, and lymph 
nodes.
A Phase I controlled study with linezolid 600 mg twice 
daily and placebo evaluated the hematological toxicity of 
tedizolid phosphate at doses of 200, 300, and 400 mg once 
daily administered for 21 days in 40 healthy subjects.84 
No hematological adverse effects or clinically meaningful 
changes in blood cell counts were reported with 200 mg once-
daily administration for 21 days. However, hematological 
changes increased with dose and duration of administration 
such that the administration of 400 mg once daily of tedizolid 
phosphate resulted in hematological alterations starting during 
the second week of treatment. These alterations were similar 
to those observed with linezolid 600 mg twice daily, and 
occurred at approximately the same time. In another study by 
the same authors, treatment discontinuation was reported in 
two patients who received 400 mg of tedizolid phosphate due 
to a decrease in reticulocyte count in one case and in white 
cell count in the other, and linezolid treatment discontinuation 
in one patient due to a decrease in reticulocyte count.85 Thus, 
only a few hematological adverse effects have been observed 
for tedizolid phosphate at a dose of 400 mg used for more than 
2 weeks. However, given that the clinical and microbiological 
efficacy is similar for the 200, 300, and 400 mg doses,55 the 
administration of lower doses could be considered to reduce 
the potential for developing myelosuppression.
Additionally, isolated cases of optic neuritis have been 
reported in patients treated with linezolid, who have had to 
discontinue treatment.86,87 Although the mechanism causing 
this is not entirely clear, a mechanism similar to that of optic 
neuropathy due to nutritional deficiency has been proposed.88 
Currently, a Phase I clinical trial is under way to evaluate the 
neurological and ophthalmologic safety of the oral administra-
tion of 200 mg of tedizolid phosphate once daily for 10 days 
in healthy adults aged between 18 and 65 years.89
Drug interactions
Tedizolid does not inhibit the monoamine oxidase (MAO) 
system in vivo, due to greater antibiotic potency relative to 
MAO inhibition. This gives it an advantage over linezolid, 
which exercises a weak, reversible, and nonselective inhi-
bition of MAO that can trigger potential interactions with 
adrenergic and serotonergic drugs. Therefore, it improves 
the profile of possible interactions with serotonin reuptake 
inhibitors and other compounds with serotonergic activity, as 
well as adrenergic agents, dietary tyramine, and endogenous 
biogenic amines with the consequent negative effects on the 
central nervous system and blood pressure.90,91
Two randomized double-blind placebo-controlled 
crossover Phase I studies have been completed evaluat-
ing the potential for tedizolid phosphate to inhibit MAO.92 
A comparison of the effects on systolic blood pressure (SBP) 
of the concomitant administration of tedizolid phosphate and 
pseudoephedrine against the administration of the antibiotic 
with placebo was investigated in 18 healthy subjects. No 
differences were observed in median maximum SBP change 
from baseline for pseudoephedrine treatment with tedizolid 
phosphate or placebo, and the number of subjects with SBP 
increases of 15 mmHg or higher were similar between groups 
(four with tedizolid phosphate and five with placebo).
Similarly, a trial in healthy adults evaluated the dose 
of tyramine needed to cause a 30 mmHg increase in SBP 
(TYR
30
) in combination with 200 mg tedizolid phosphate 
once daily or with placebo. Modest increases in sensitivity 
to tyramine were observed with tedizolid phosphate relative 
to placebo, but the TYR
30
 with tedizolid (339 mg) was only 
28% lower that the TYR
30
 with placebo and was high enough 
to mean that adverse vascular effects due to intake of food 
with a high tyramine content are unlikely.
The potential for serotonin syndrome, a potentially fatal 
consequence of MAO inhibitor compounds, was evaluated 
in a mouse head-twitch model92 showing that tedizolid 
was comparable to placebo (vehicle) in its potential to 
induce head twitches, an established marker of serotonergic 
 activity. In contrast, linezolid induced a head-twitch response 
 comparable to fluoxetine, a compound known to increase 
serotonin concentrations by blocking reuptake.
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Stability and compatibility
The prodrug demonstrated water solubility greater than 
50 mg/mL and excellent chemical stability, remaining unal-
tered after 8 hours in solutions with different pH, including a 
glycosylated saline solution with a practically neutral pH of 
6.47.31 The physicochemical properties of the prodrug resolve 
the water solubility problems observed during the develop-
ment of other molecules, such as DA-7867, whose reduced 
water solubility and bioavailability by the oral administration 
route limited its use, despite its high antimicrobial activity.93 
The compatibility of tedizolid phosphate has not been the 
object of any study to date; however, the dose of the drug 
was administered diluted in 250 mL of saline solution in two 
studies in healthy adults.33,78
Conclusion
The emergence of ABSSSI with microorganisms resistant 
to current treatment options indicates a need to expand the 
available therapeutic arsenal. Tedizolid phosphate showed 
favorable results in the treatment ABSSSI in the first 
Phase III clinical trial. Tedizolid has more potent in vitro 
activity than linezolid against strains of Staphylococcus spp., 
 Streptococcus spp., and Enterococcus spp., including strains 
resistant to linezolid and strains with reduced susceptibility to 
vancomycin or daptomycin. Moreover, tedizolid phosphate 
shows favorable pharmacokinetic and safety profiles that, 
along with a reduced potential for drug interactions, make 
this molecule an attractive option in circumstances in which 
the activity of currently available agents is limited.
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